Association details:
Evidence Level:
Sensitive: C3 – Early Trials

411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation

Published date:
The maximal tumor shrinkage rate following osimertinib treatment in the patients with AXL expression scores of 0 and 1+ was higher than that in patients with AXL expression scores of 2+ and 3+ (44.12% vs. 25.93%, p = 0.094)….Pre-treatment AXL expression in tumors may be a promising predictor of osimertinib treatment efficacy in patients with EGFR-mutated NSCLC.